Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Feb;19(2):211.
doi: 10.1634/theoncologist.2013-0410. Epub 2014 Jan 23.

Src inhibition is still a relevant target in pancreatic cancer

Thomas J George Jr  1 , Jose G Trevino, Chen Liu
Affiliations
Comment

Src inhibition is still a relevant target in pancreatic cancer

Thomas J George Jr et al. Oncologist. 2014 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Comment on

References

    1. Chee CE, Krishnamurthi S, Nock CJ, et al. Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. The Oncologist. 2013;18:1091–1092. - PMC - PubMed
    1. Kaiser J. Biomedicine. Rare cancer successes spawn “exceptional” research efforts. Science. 2013;340:263. - PubMed
    1. Ito H, Gardner-Thorpe J, Zinner MJ, et al. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery. 2003;134:221–226. - PubMed
    1. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of Src tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res. 2004;10:8028–8036. - PubMed
    1. Nagaraj NS, Smith JJ, Revetta F, et al. Targeted inhibition of Src kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther. 2010;9:2322–2332. - PMC - PubMed

MeSH terms

Associated data